Table 3

Clinical activity score for the teprotumumab and placebo groups

StudyCaseBaseline
study eye
Week 24
study eye
Baseline
fellow eye
Week 24
fellow eye
A: Clinical activity score in patients who received teprotumumab
 315100
 325010
 334040
 245141
 254040
 267474
 275040
 284110
 294000
 2105120
 Mean50.82.70.5
 SD0.91.22.31.3
B: Clinical Activity Score in patients who received placebo
 Phase 317373
 Phase 325040
 Phase 335252
 Phase 347252
 Phase 355544
 Phase 366544
 Phase 275151
 Phase 284444
 Phase 294530
 Phase 2106341
 Phase 2116565
 Phase 2125322
 Mean5.43.24.42.3
 SD11.71.31.7